The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | DESTINY-Gastric02: 2L T-DXd in HER2+ gastric cancers
Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of the Phase II DESTINY-Gastric02 study (NCT04014075) presented at this years European Society for Medical Oncology (ESMO) 2021 congress. In this study, second-line trastuzumab deruxtecan (T-DXd) in Western patients with HER2-positive gastric/gastroesophageal junction cancer demonstrated clinical efficacy and a manageable safety profile. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
